Italia markets closed

Ion Beam Applications SA (0GZK.L)

YHD - YHD Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
208.440.000,00+3,50 (+0,00%)
Alla chiusura: 6:07PM EDT
Schermo intero
Chiusura precedenteN/D
Rendimento dall'inizio dell'anno (YTD)N/D
Coefficiente di spesa (netto)N/D
CategoriaN/D
Ultimo guadagno in conto di capitaleN/D
Rating di MorningStarN/D
Rating di Morningstar (rischio)N/D
Rating di sostenibilitàN/D
Attività netteN/D
Beta (5 anni mensile)N/D
RendimentoN/D
Rendimento medio 5aN/D
Turnover portafoglio titoliN/D
Ultimo dividendoN/D
Media per la categoriaN/D
Data di inizio disponibilitàN/D
  • GlobeNewswire

    Iba – Transparency Notification

    (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, November 22th, 2021, 17.40 Summary of the notification IBA (Ion Beam Application), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on November

  • GlobeNewswire

    IBA and the Oncology Reference Center of Aviano, Italy, sign contract to install a Proteus®ONE Proton Therapy system

    Louvain-La-Neuve, Belgium, November 19, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract for the installation of a Proteus®ONE1 proton therapy turnkey solution with the Oncology Reference Center (C.R.O.) in Aviano, Italy. IBA was selected as the preferred supplier following a comprehensive vendor selection pr

  • GlobeNewswire

    IBA and NorthStar Medical Radioisotopes Sign Contract for Rhodotron® Electron Beam Accelerator for Commercial Production of Therapeutic Radioisotope Actinium-225 (Ac-225)

    Louvain-La-Neuve, Belgium, and BELOIT, Wis., USA November 18, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and NorthStar Medical Radioisotopes, LLC, (‘NorthStar’) a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced a new contract in which NorthStar will purchase a third Rhodotron® TT300 HE electron beam accelerator from IBA.